Man Group PLC Verastem, Inc. Transaction History

Man Group PLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	BUY	$1.02 - $1.83 $4,672 - $8,383	4,581 Added 39.15%	16,281 $19,000
Q1 2022 May 16, 2022	BUY	$1.06 - $2.1 $12,402 - $24,570	11,700 New	11,700 $16,000
Q2 2019 Aug 14, 2019	SELL	$1.25 - $3.14 $627,225 - $1.58 Million	-501,780 Closed	0 $0
Q1 2019 May 15, 2019	SELL	$2.79 - $4.09 $52,033 - $76,278	-18,650 Reduced 3.58%	501,780 $1.49 Million
Q4 2018 Feb 14, 2019	SELL	$3.23 - $7.01 $733,113 - $1.59 Million	-226,970 Reduced 30.37%	520,430 $1.75 Million
Q3 2018 Nov 14, 2018	BUY	$6.86 - $9.97 $5.13 Million - $7.45 Million	747,400 New	747,400 $5.42 Million
Q2 2018 Aug 14, 2018	SELL	$2.88 - $8.67 $260,887 - $785,380	-90,586 Closed	0 $0
Q1 2018 May 15, 2018	BUY	$2.92 - $3.81 $264,511 - $345,132	90,586 New	90,586 $270,000

297K

Ticker VSTM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 210,000,000
Market Cap $1.29B
Description
Verastem, Inc., a development-stage biopharmaceutical company, focusing on developing and commercializing drugs for the treatment of cancer. Its product in development includes VS-6766, a dual rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) clamp that blocks MEK kinase activity and the ability of RAF to phosphorylat...

Get notified when there are updates to the investment portfolio of Man Group PLC, based on Form 13F filings with the SEC.

Stay updated on Man Group PLC with notifications on news.